Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 aAGREE-REX Scores For Specific Items, Overall Items (across the 11 Items), and Overall Assessments

From: Assessment of the quality of recommendations from 161 clinical practice guidelines using the Appraisal of Guidelines for Research and Evaluation–Recommendations Excellence (AGREE-REX) instrument shows there is room for improvement

Practice Guidelines (PG) Features

Specific Items Means

Overall Means

Overall Assessments

#

PGs

Evidence

Clinical Relevance

Patient/pop. Relevance

Implement-ation Relevance

Values Developers

Values Users

Values Patient/Pop

Values Policy

Alignment of Values

Local Applicability

Resources, Tools, Capacity

Mean Overall Score

% Score Mean

Clinical Credibility

Implement- ability

All Guidelines

5.15 (1.33)

5.47 (1.18)

4.87 (1.33)

4.46 (1.52)

4.61 (1.45)

4.28 (1.52)

3.85 (1.61)

3.44 (1.53)

3.42 (1.44)

3.56 (1.47)

3.49 (1.44)

4.23 (1.14)

54 (19)

4.78 (1.24)

4.19 (1.23)

161

Type of Organization

 Government Supported

5.61 (1.14)

5.95 (0.8)

5.57 (0.98)

5.48 (0.89)

5.26 (1.2)

4.97 (1.14)

4.83 (1.34)

4.56 (1.15)

4.11 (1.32)

4.52 (1.3)

4.41 (1.11)

5.02 (0.77)

67 (13)

5.28 (0.96)

4.85 (1.07)

46

 Professional Societies

4.98 (1.35)

5.24 (1.26)

4.57 (1.36)

4.04 (1.55)

4.30 (1.48)

3.98 (1.58)

3.41 (1.52)

2.99 (1.46)

3.1 (1.38)

3.17 (1.39)

3.06 (1.39)

3.89 (1.2)

48 (19)

4.56 (1.31)

3.89 (1.21)

109

 Other or Not Clear

4.83 (1.63)

6.17 (0.68)

5.00 (1.41)

4.42 (1.24)

5.17 (0.93)

4.5 (1.38)

4.42 (2.04)

3.00 (0.89)

3.75 (1.63)

3.33 (0.82)

4.25 (1.29)

4.44 (0.99)

57 (17)

4.83 (0.82)

4.50 (0)

6

p-value

0.021

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.004

<0.001

 

Country

 US

5.06 (1.39)

5.33 (1.28)

4.68 (1.4)

4.17 (1.58)

4.51 (1.49)

4.12 (1.62)

3.61 (1.66)

3.08 (1.47)

3.31 (1.54)

3.26 (1.47)

3.22 (1.47)

4.03 (1.21)

51 (20)

4.62 (1.31)

3.98 (1.26)

89

 UK

5.26 (1.23)

5.74 (0.9)

5.22 (1.13)

5.04 (1.25)

4.86 (1.39)

4.76 (1.21)

4.23 (1.31)

4.16 (1.41)

3.66 (1.26)

4.18 (1.48)

4.12 (1.41)

4.66 (0.95)

61 (16)

5.06 (1.06)

4.51 (1.19)

46

 Canada

5.46 (1.21)

5.87 (0.64)

5.17 (1.19)

4.75 (1.5)

4.67 (1.51)

4.5 (1.58)

4.46 (2)

3.87 (1.61)

3.79 (1.48)

3.83 (1.27)

3.42 (1)

4.53 (1.08)

59 (18)

4.92 (1.12)

4.50 (1.1)

12

 International

5.18 (1.38)

5.18 (1.44)

4.64 (1.42)

4.18 (1.47)

4.39 (1.47)

3.54 (1.31)

3.64 (1.67)

2.96 (1.39)

2.96 (1.18)

3.18 (0.99)

3.25 (1.14)

3.91 (0.98)

49 (16)

4.75 (1.38)

4.21 (1.03)

14

p-value

0.7

0.1146

0.1192

0.011

0.5495

0.025

0.0932

<0.001

0.2609

0.0036

0.0056

0.0106

0.0106

0.2649

0.0851

 
  1. aMean (SD); US United States, UK United Kingdom, Implement implementability, Patient/Pop Patients/population